Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 6/20 | 0.42 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | HBB | P68871 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10370258 | 0.98 | CYP2A6 (0.53) | CYP2A6DYRK1ACA2CA12ALDH1A1 | |
| Sulfuric Acid SCHEMBL7376046 | 0.88 | CA2 (0.46) | CYP2A6DYRK1ACA2CA12ALDH1A1 | |
| SCHEMBL25167022 | 0.83 | DYRK1A (0.68) | CYP2A6DYRK1ACA2CA12ALDH1A1 | |
| SCHEMBL397816 | 0.81 | ALDH1A1 (0.42) | CYP2A6DYRK1ACA2ALDH1A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL15880793 | 0.79 | ALDH1A1 (0.41) | CYP2A6DYRK1ACA2ALDH1A1CYP3A4 | |
| SCHEMBL164774 | 0.73 | CYP2A6 (0.50) | CYP2A6DYRK1ACA2CA12ALDH1A1 | |
| SCHEMBL17010916 | 0.73 | CYP2A6 (0.52) | CYP2A6DYRK1ACA2CA12ALDH1A1 | |
| SCHEMBL14756142 | 0.73 | CYP2A6 (0.72) | CYP2A6DYRK1AALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL155613 | 0.71 | CYP2A6 (0.50) | CYP2A6DYRK1ACA2CA12PTPRC | |
| SCHEMBL2011544 | 0.71 | CYP2A6 (0.50) | CYP2A6DYRK1ACA2CA12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109134267-B | Synthetic method of aromatic amine compound | 北京大学 | 2020-11-17 | — | — | CN | claimed |
| CN-109456216-A | A kind of no catalyst is reacted without aromatic amine under the conditions of promotor with the amine that turns of amide derivatives | 湘潭大学 | 2019-03-12 | — | — | CN | claimed |
| CN-109134267-A | A kind of synthetic method of aromatic amine compounds | 北京大学 | 2019-01-04 | — | — | CN | claimed |
| EP-3568399-B1 | AZIRIDINE SPINOSYN DERIVATIVES AND METHODS OF MAKING | AGRIMETIS LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| CN-120152713-A | Tricyclic aryl derivatives and compositions and methods thereof | 昂胜医疗科技公司 | 2025-06-13 | — | — | CN | disclosed |
| EP-4561562-A2 | TRICYCLIC ARYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | Ensem Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2025097104-A1 | THIENYL COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PGI DRUG DISCOVERY LLC (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096855-A1 | DEGRADERS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025064853-A1 | RIPK3 INHIBITORS AND METHODS OF USE | Momentum Therapeutics, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250092031-A1 | RIPK3 INHIBITORS AND METHODS OF USE | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2025-03-20 | — | — | US | disclosed |
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | VIVIDION THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| EP-0340010-A2 | Heterocyclic nitromethane derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-11-02 | — | — | EP | disclosed |
| US-4788192-A | TOPICALLY APPLYING; FOR GLAUCOMA | MERCK & CO., INC. (US) | 1988-11-29 | — | — | US | disclosed |
| US-4695571-A | Tricyclic oxindole antiinflammatory agents | PFIZER INC. (US) | 1987-09-22 | — | — | US | disclosed |
| US-4668697-A | Elevated intraocular pressure lowering benzo-[b]-thiophene-2-sulfonamide derivatives, compositions, and method of use therefor | MERCK & CO., INC. (US) | 1987-05-26 | — | — | US | disclosed |
| WO-1986001510-A1 | TRICYCLIC OXINDOLE ANTIINFLAMMATORY AGENTS | PFIZER INC. (US) | 1986-03-13 | — | — | WO | disclosed |
| EP-0129478-A2 | 2-Sulfamoylbenzo (b) thiophene derivatives, their preparation and pharmaceutical composition for the treatment of elevated intraocular pressure | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | disclosed |
| EP-0065393-B1 | PYRROLE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-12-27 | — | — | EP | disclosed |
| US-4443465-A | Aldose reductase inhibitory pyrrole derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-04-17 | — | — | US | disclosed |
| US-4120960-A | DIURETICS, SALURESIS | THE BOOTS COMPANY LIMITED (GB) | 1978-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092031-A1 | RIPK3 INHIBITORS AND METHODS OF USE | RIPK3, RIPK1, RIPK2 | CYP2A6 4841/4885DYRK1A 2572/4885CA2 3746/4885 |
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | KRAS, HRAS, NRAS | CYP2A6 3738/4885DYRK1A 2455/4885CA2 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.